HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiang, R. Articles by Reisfeld, R. A. Search for Related Content PubMed PubMed Citation Articles by Xiang, R. Articles by Reisfeld, R. A.

T Cell Memory Against Colon Carcinoma Is Long-Lived in the Absence of Antigen¹

Rong Xiang^*, Holger N. Lode^*, Stephen D. Gillies and Ralph A. Reisfeld^2,*

^* Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037; and Lexigen Pharmaceuticals, Lexington, MA 02173

Eradication of established colon carcinoma metastases is a major goal for adjuvant immunotherapy of this disease. This was accomplished in a murine model by targeting IL-2 to the tumor microenvironment with a recombinant Ab-IL-2 fusion protein (huKS1/4-IL-2). The generation of a long-lived protective immunity was demonstrated by a 10- to 14-fold increase in CTL precursor (pCTL) frequency and induction of genes encoding Th1 cytokines, followed by the generation of tumor-specific CD8⁺ T effector cells, some of which differentiated into long-lived T memory cells. The frequency of pCTL correlated with enhanced immune protection against tumor cell challenge, and long-lived T cell memory was maintained in syngeneic SCID mice in the absence of tumor Ag. Tumor cell challenge of these SCID mice, concomitant with a boost of two noncurative doses of huKS1/4-IL-2 fusion protein, resulted in the generation of primed CD8⁺ T effector cells with concurrent release of Th1 cytokines. These events culminated in the complete rejection of the tumor cell challenge and prevention of pulmonary metastases. Taken together, the data suggest that T cell memory against colon carcinoma can be maintained in the absence of Ag.

This article has been cited by other articles:

				M. Camus, M. Tosolini, B. Mlecnik, F. Pages, A. Kirilovsky, A. Berger, A. Costes, G. Bindea, P. Charoentong, P. Bruneval, et al. Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence Cancer Res., March 15, 2009; 69(6): 2685 - 2693. [Abstract] [Full Text] [PDF]

				F. Pages, J. Galon, and W. H. Fridman The essential role of the in situ immune reaction in human colorectal cancer J. Leukoc. Biol., October 1, 2008; 84(4): 981 - 987. [Abstract] [Full Text] [PDF]

				J. Galon, W.-H. Fridman, and F. Pages The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective Cancer Res., March 1, 2007; 67(5): 1883 - 1886. [Abstract] [Full Text] [PDF]

				J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, September 29, 2006; 313(5795): 1960 - 1964. [Abstract] [Full Text] [PDF]

				F. Pages, A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, et al. Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer N. Engl. J. Med., December 22, 2005; 353(25): 2654 - 2666. [Abstract] [Full Text] [PDF]

				Y. Luo, H. Zhou, M. Mizutani, N. Mizutani, C. Liu, R. Xiang, and R. A. Reisfeld A DNA Vaccine Targeting Fos-Related Antigen 1 Enhanced by IL-18 Induces Long-lived T-Cell Memory against Tumor Recurrence Cancer Res., April 15, 2005; 65(8): 3419 - 3427. [Abstract] [Full Text] [PDF]

				J. M. Ruehlmann, R. Xiang, A. G. Niethammer, Y. Ba, U. Pertl, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld MIG (CXCL9) Chemokine Gene Therapy Combines with Antibody-Cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma Cancer Res., December 1, 2001; 61(23): 8498 - 8503. [Abstract] [Full Text] [PDF]

				S. A. Holden, Y. Lan, A. M. Pardo, J. S. Wesolowski, and S. D. Gillies Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents Clin. Cancer Res., September 1, 2001; 7(9): 2862 - 2869. [Abstract] [Full Text] [PDF]

				A. G. Niethammer, R. Xiang, J. M. Ruehlmann, H. N. Lode, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma Cancer Res., August 1, 2001; 61(16): 6178 - 6184. [Abstract] [Full Text] [PDF]

				P. M. J. McLaughlin, M. C. Harmsen, W. H. A. Dokter, B.-J. Kroesen, H. van der Molen, M. G. L. Brinker, H. Hollema, M. H. J. Ruiters, C. H. C. M. Buys, and L. F. M. H. de Leij The Epithelial Glycoprotein 2 (EGP-2) Promoter-driven Epithelial-specific Expression of EGP-2 in Transgenic Mice: A New Model to Study Carcinoma-directed Immunotherapy Cancer Res., May 1, 2001; 61(10): 4105 - 4111. [Abstract] [Full Text]

				C.-C. Ku, J. Kappler, and P. Marrack The Growth of the Very Large CD8+ T Cell Clones in Older Mice Is Controlled by Cytokines J. Immunol., February 15, 2001; 166(4): 2186 - 2193. [Abstract] [Full Text] [PDF]

				M. Imboden, K. R. Murphy, A. L. Rakhmilevich, Z. C. Neal, R. Xiang, R. A. Reisfeld, S. D. Gillies, and P. M. Sondel The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy Cancer Res., February 1, 2001; 61(4): 1500 - 1507. [Abstract] [Full Text]